Breaking News Instant updates and real-time market news.

INSY

Insys Therapeutics

$11.87

-0.34 (-2.78%)

06:52
10/13/16
10/13
06:52
10/13/16
06:52

Insys Therapeutics sees preliminary Q3 revenues from Subsys $54M-$55M

Insys Therapeutics' preliminary estimated Q3 revenues from Subsys sublingual spray will be $54M-$55M. The company believes it will be cash-flow positive at this level of sales and will be able to meet its overall objectives of new product development and future growth. Estimated revenues for the quarter reflect a decline in prescriptions as the company continues to believe that the ongoing and heightened publicity surrounding the national opioid epidemic and continuing governmental and regulatory scrutiny of the company and the transmucosal immediate release fentanyl class has resulted in a sensitivity by some healthcare providers to prescribe and dispense TIRF medications.

  • 29

    Nov

INSY Insys Therapeutics
$11.87

-0.34 (-2.78%)

04/14/16
04/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Symantec (SYMC) initiated with a Sell at Evercore ISI by analyst Ken Talanian, who found it unclear whether the current management will be able to "facilitate significant change." He adds that the stock's current valuation overestimates the company's ability to reduce cost and return to growth. 2. Insys Therapeutics (INSY) initiated with a Buy at Janney Capital with analyst Ken Trbovich saying the company's pipeline is "too compelling to ignore." He said that the FDA approval and launch of its Syndros product should offset the weakness from Subsys. 3. Simon Property (SPG) initiated with a Buy at Mizuho. 4. AcelRx (ACRX) initiated with a Neutral at Janney Capital. 5. Intuit (INTU) initiated with a Buy at Brean Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/16
JANY
07/05/16
NO CHANGE
Target $22
JANY
Buy
Insys approval of Syndros may trigger short squeeze, says Janney Capital
Janney Capital analyst Ken Trbovich said in a note published on July 1 that the potential approval of Syndros was one of three potential catalysts expected in the next six months that may trigger a short squeeze in shares of Insys Therapeutics. Insys announced this morning that the FDA has approved Syndros for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. In his prior note, Trbovich set a $22 fair value estimate and Buy rating on Insys shares, which are up 20% to $16.18 in pre-market trading.
08/04/16
JEFF
08/04/16
NO CHANGE
Target $22
JEFF
Buy
Insys Therapeutics price target raised to $22 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Insys Therapeutics to $22 saying Subsys scripts appear to have stabilized following the company's in-line Q2 results. The most important element of earnings call was the comment that "we're very optimistic that it [settlement with the DOJ] could happen by end of the year," Steinberg tells investors in a research note. The analyst views the Department of Justice investigation as "by far the most important overhang to the story." He keeps a Buy rating on Insys.
08/26/16
JANY
08/26/16
NO CHANGE
Target $22
JANY
Buy
Illinois 'highly unlikely' to be able to bar Insys sales, says Janney Capital
Janney Capital analyst Ken Trbovich said he thinks it is "highly unlikely" that Illinois' Attorney General will succeed with her proposal to ban Insys Therapeutics from doing business in the state, pointing to the fact that a similar attempt by Massachusetts in 2014 was struck down by a federal judge. This story, and the trading in its wake yesterday, clearly indicate Insys has headline risks from ongoing state and federal investigations, acknowledged Trbovich, but he thinks the risk will be eliminated by a settlement for an amount the company can manage from its existing cash. The analyst keeps a Buy rating and $22 fair value estimate on Insys shares, which fell about 4.6% yesterday to close at $14.98.

TODAY'S FREE FLY STORIES

USO

United States Oil Fund

$12.97

0.19 (1.49%)

06:55
01/24/18
01/24
06:55
01/24/18
06:55
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$39.85

0.16 (0.40%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CWST

Casella Waste

$24.26

0.09 (0.37%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Upgrade
Casella Waste rating change  »

Casella Waste upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$20.44

-2.99 (-12.76%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$89.75

10.55 (13.32%)

06:53
01/24/18
01/24
06:53
01/24/18
06:53
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$43.66

-0.97 (-2.17%)

06:52
01/24/18
01/24
06:52
01/24/18
06:52
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$74.75

0.24 (0.32%)

06:51
01/24/18
01/24
06:51
01/24/18
06:51
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAP

Universal Stainless & Alloy

$22.85

0.44 (1.96%)

06:51
01/24/18
01/24
06:51
01/24/18
06:51
Earnings
Universal Stainless & Alloy reports Q4 EPS $1.06 with items vs. (22c) a year ago »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$25.13

-0.28 (-1.10%)

06:50
01/24/18
01/24
06:50
01/24/18
06:50
Hot Stocks
RPC, Inc. raises quarterly dividend by 43% to 10c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    May

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Hot Stocks
Baker Hughes CEO: Continue to see improvement in activity »

Lorenzo Simonelli, BHGE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$25.13

-0.28 (-1.10%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Earnings
RPC, Inc. reports Q4 adjusted EPS 27c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    May

PBYI

Puma Biotechnology

$90.90

-3.05 (-3.25%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Downgrade
Puma Biotechnology rating change  »

Cowen downgrades Puma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$36.96

0.11 (0.30%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZO

MarineMax

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Earnings
Breaking Earnings news story on MarineMax »

MarineMax raises FY18 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MPX

Marine Products

$13.97

0.17 (1.23%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Hot Stocks
Marine Products raises quarterly dividend to 10c per share from 7c per share »

Marine Products announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SJB

ProShares Short High Yield

$22.99

-0.0507 (-0.22%)

06:48
01/24/18
01/24
06:48
01/24/18
06:48
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.88

0.26 (0.30%)

06:48
01/24/18
01/24
06:48
01/24/18
06:48
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$120.18

0.52 (0.43%)

06:48
01/24/18
01/24
06:48
01/24/18
06:48
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZO

MarineMax

06:48
01/24/18
01/24
06:48
01/24/18
06:48
Earnings
MarineMax reports Q1 adjusted EPS 23c, consensus (1c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Hot Stocks
Baker Hughes reports backlog of $21B at Q4-end »

Backlog grew in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$123.71

0.53 (0.43%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPX

Marine Products

$13.97

0.17 (1.23%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Earnings
Marine Products reports Q4 EPS 10c, one estimate 12c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

CS

Credit Suisse

$19.32

-0.02 (-0.10%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Periodicals
Credit Suisse CEO says 2018 'started very well', Reuters reports »

Credit Suisse CEO Tidjane…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Hot Stocks
Baker Hughes reports Q4 orders of $5.8B »

Up 1% sequentially and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

$16.08

0.04 (0.25%)

06:46
01/24/18
01/24
06:46
01/24/18
06:46
Technical Analysis
iShares Silver Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.